2018 ASMI AGM elects new Board Director 28 November 2018 The Australian Self Medication Industry (ASMI) held its AGM in Parliament House, Canberra, yesterday. Doug Cunningham, Managing Director, Johnson & Johnson Pacific and Mark Sargent, General Manager, ANZ Consumer Health Bayer Australia were re-elected to the Board of Directors. Joining the Board of Directors for […]

1. Cough Medicine 03 October 2018 The Australian Self Medication Industry (ASMI) seeks to reassure Australians that cough and cold medicines containing pholcodine have a long history of use and a well-established, favourable safety profile. Pholcodine is used as a common cough suppressant and is an active ingredient in some cough and cold products available […]

ACMS to consider MR Paracetamol up-schedule 31 August 2018 Late yesterday, the TGA requested that the Advisory Committee on Medicines Scheduling (ACMS) consider up-scheduling modified-release (MR) paracetamol from S2 to S3. The TGA’s proposal will not affect consumer access to immediate-release paracetamol products which are currently available for self-selection in grocery and pharmacy. Scheduling decisions, […]

International Self Care Day – Feel Good, 24/7 24 July 2018 Today is International Self Care Day with the theme ‘Feel Good, 24/7’. Self care refers to the activities individuals, families and communities undertake on their own behalf to prevent disease, enhance health and treat minor illness. Greater self care results in improved health outcomes […]

ASMI proud to be part of Health Care Ethical Framework 20 July 2018 The Australian Self Medication Industry (ASMI) is proud to be one of the 50 signatory bodies to the Australian Consensus Framework for Ethical Collaboration in the Healthcare Sector. The consensus framework for ethical practices in health care, developed in collaboration with Australian health […]